Standardization criteria for the detection of BCR/ABL fusion in interphase nuclei of chronic myelogenous leukemia patients by fluorescence in situ hybridization

被引:46
作者
Cohen, N
Novikov, I
Hardan, I
Esa, A
Brok-Simoni, F
Amariglio, N [1 ]
Rechavi, G
Ben-Bassat, I
Trakhtenbrot, L
机构
[1] Tel Aviv Univ, Sackler Sch Med, Chaim Sheba Med Ctr, Inst Hematol, IL-52621 Tel Hashomer, Israel
[2] Heidelberg Univ, Kirchhoff Inst Phys, Heidelberg, Germany
关键词
D O I
10.1016/S0165-4608(00)00315-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fluorescence in situ hybridization (FISH), as a new clinical test, is not presently standardized. For practical reasons, each laboratory must build its own criteria. In this work, we present our standardization criteria for clinical practice, which include not only the methods for cell fixation, specimen preparation, and hybridization conditions, but mainly the definition of false-positive range and the scoring criteria of microscopic analysis. These include signal assessment, difference between individual microscopists, evaluation of specimen homogeneity, and the minimum number of scored nuclei required for a clinically reliable result. For this purpose, we analyzed by FISH 24 healthy volunteer donors, 31 patients affected by non-chronic myelogenous leukemia (CML) hematological malignancies, 47 CML patients at diagnosis, and 82 CML patients during treatment for the BCR/ABL fusion. In this article, we present several quality control and assurance methods that can be useful in providing standardization of the FISH technique. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:102 / 108
页数:7
相关论文
共 29 条
[1]   DETECTION OF MINIMAL RESIDUAL DISEASE STATE IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS USING FLUORESCENCE IN-SITU HYBRIDIZATION [J].
AMIEL, A ;
YARKONI, S ;
SLAVIN, S ;
OR, R ;
LORBERBOUMGALSKI, H ;
FEJGIN, M ;
NAGLER, A .
CANCER GENETICS AND CYTOGENETICS, 1994, 76 (01) :59-64
[2]   DETECTION OF CHIMERIC BCR-ABL GENES ON BONE-MARROW SAMPLES AND BLOOD SMEARS IN CHRONIC MYELOID AND ACUTE LYMPHOBLASTIC-LEUKEMIA BY IN-SITU HYBRIDIZATION [J].
BENTZ, M ;
CABOT, G ;
MOOS, M ;
SPEICHER, MR ;
GANSER, A ;
LICHTER, P ;
DOHNER, H .
BLOOD, 1994, 83 (07) :1922-1928
[3]   Comparative study of three-dimensional localization accuracy in conventional, confocal laser scanning and axial tomographic fluorescence light microscopy [J].
Bradl, J ;
Rinke, B ;
Esa, A ;
Edelmann, P ;
Krieger, H ;
Schneider, B ;
Hausmann, M ;
Cremer, C .
OPTICAL BIOPSIES AND MICROSCOPIC TECHNIQUES, PROCEEDINGS OF, 1996, 2926 :201-206
[4]   A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia [J].
Buño, I ;
Wyatt, WA ;
Zinsmeister, AR ;
Dietz-Band, J ;
Silver, RT ;
Dewald, GW .
BLOOD, 1998, 92 (07) :2315-2321
[5]  
Chase A, 1997, GENE CHROMOSOME CANC, V18, P246, DOI 10.1002/(SICI)1098-2264(199704)18:4<246::AID-GCC2>3.0.CO
[6]  
2-0
[7]   Some observations on fluorescence in situ hybridization evaluation of chronic myelocytic leukemia [J].
Chen, Z ;
Notohamiprodjo, M ;
Richards, PD ;
Lane, FB ;
Morgan, R ;
Stone, JF ;
Sandberg, AA .
CANCER GENETICS AND CYTOGENETICS, 1997, 98 (01) :1-3
[8]   APPRECIATION OF THE SIGNIFICANCE OF CYTOGENETIC AND FISH ANALYSIS OF BONE-MARROW IN CLINICAL ONCOLOGY [J].
CHEN, Z ;
MORGAN, R ;
STONE, JF ;
SANDBERG, AA .
CANCER GENETICS AND CYTOGENETICS, 1994, 78 (01) :10-14
[9]   Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-alpha (IFN-alpha) therapy [J].
CoxFroncillo, MC ;
Cantonetti, M ;
Masi, M ;
Lentini, R ;
Giudiceandrea, P ;
Maffei, L ;
Tribalto, M ;
Amadori, S ;
Papa, G .
CANCER GENETICS AND CYTOGENETICS, 1995, 84 (01) :15-18
[10]  
D'Agostino R.B., 1986, GOODNESS OF FIT